Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
5(100.0%)
5Total
N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07464977Not ApplicableNot Yet Recruiting

EMG and Delta Function in Standard RTSA vs Lateralization

Role: lead

NCT05954637Completed

Correlation of Structure and Function in Glaucoma

Role: lead

NCT04829955Not ApplicableCompleted

Eccentric Manual Resistance Training in Patients With Ischemic CMP

Role: lead

NCT06132776Not ApplicableRecruiting

The Mamma HiToP Study

Role: lead

NCT06048471Not ApplicableCompleted

High Tone Therapy for Chemotherapy Induced Neuropathy

Role: lead

NCT05058742Not ApplicableUnknown

Non-invasive Nervus Vagus Stimulation in Patients With COVID-19 and ARDS

Role: lead

All 6 trials loaded